Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Simnova Acquires China Rights to Circular RNA CAR-T Therapies from Orna

publication date: Jan 9, 2023

Simnova Biotherapeutics acquired China rights to novel CAR-T cell therapies developed by Orna Therapeutics, a Cambridge, MA biotech. Simnova will have greater China rights to specific programs built on Orna's novel isCAR technology, including Orna's lead anti-CD19 in situ CAR (isCAR) program, ORN-101, which is based on Orna’s novel engineered circular RNA (oRNA) technology. Simnova, a Cambridge, MA-Shanghai company, is an affiliate of Simcere Investment Group and known as Xianbo Biotech in China. It develops off-the-shelf CAR-NK and BiTE-armed CAR-T cell therapies. More details....

See our other articles on Simcere.

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital